Trial Profile

Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
Indications Bladder cancer; Carcinoma
Focus Pharmacogenomic; Proof of concept; Therapeutic Use

Most Recent Events

10 Mar 2025 Time frame of primary endpoint changed from Less than 10 weeks to Baseline and delivery of surgery sample to lab (Up to 3 months).
01 Feb 2024 Planned End Date changed from 31 Oct 2026 to 22 Nov 2026.
07 Dec 2023 Planned End Date changed from 1 Jun 2024 to 31 Oct 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com